Skip to main content
SnowWorld N.V. logo

SnowWorld N.V. — Investor Relations & Filings

Ticker · SNOW ISIN · NL0010627865 LEI · 724500UPZNWHB9J3FQ35 AS Arts, sports and recreation
Open in API
Filings indexed 270 across all filing types
Latest filing 2009-12-21 Regulatory Filings
Country NL Netherlands
Listing AS SNOW

About SnowWorld N.V.

https://www.snowworld.com/en

SnowWorld N.V. operates a portfolio of large-scale indoor ski resorts, providing year-round winter sports and leisure experiences. The company's core offering includes indoor slopes with real snow for skiing and snowboarding, catering to all ages and skill levels. Services encompass recreational access, lessons, and equipment rentals. In addition to its primary winter sports activities, select venues are equipped with complementary facilities such as restaurants, hotels, and other attractions like tubing tracks and outdoor adventure parks. A notable location, SnowWorld Landgraaf, is one of Europe's largest indoor ski resorts and features the world's only indoor FIS-certified race course, highlighting the company's focus on high-quality facilities.

Recent filings

Filing Released Lang Actions
Interim-analyse driejarige oralgen grasposllen studie
Regulatory Filings Classification · 95% confidence The document is titled "PERSBERICHT" (Press Release) and announces the completion of the first interim analysis of a multi-year clinical study (AB0801) for a product called Oralgen® Graspollen. It explicitly states that the results are being kept blinded for scientific integrity and will be published later. The document is short (4277 characters) and functions as an update on a scientific/clinical development process, rather than being the full financial report (10-K, IR) or the final results announcement. Since it is an announcement regarding ongoing clinical trials and scientific progress, it does not fit neatly into the specific financial categories like ER, IR, or CAP. Given the nature of reporting on clinical trial progress and the general press release format, the most appropriate general category is Regulatory Filings (RNS), as it is a formal, non-financial regulatory/corporate update that doesn't match the other specific definitions. It is not an Earnings Release (ER) or Interim Report (IR) as it contains no financial performance data, only clinical trial status.
2009-12-21 Dutch
Interim-analyse driejarige oralgen grasposllen studie
Regulatory Filings Classification · 87% confidence The document is titled 'PRESS RELEASE' and announces the finalization of the 'FIRST INTERIM ANALYSIS THREE-YEAR ORALGEN® GRASS POLLEN STUDY'. It details the status of a clinical study (AB0801), mentions that results are blinded, and states that definitive results will be published later. This is not a full financial report (like 10-K or IR), nor is it a formal earnings release (ER) focusing on financial metrics. It is an announcement regarding ongoing clinical development and research progress, which often falls under general investor relations or regulatory updates. Since it is a specific announcement about a study update that doesn't fit the defined categories like LTR (Legal) or CAP (Financing), and it is a formal press release, the most appropriate general category is Regulatory Filings (RNS), as it is a non-standard, material announcement. However, given the content is purely about R&D progress and study status, and it is a press release, it is a material event disclosure. If a more specific category existed for R&D updates, that would be chosen. In the absence of one, RNS serves as the best fit for a general, material regulatory/investor announcement that isn't a core financial filing or management change.
2009-12-21 Dutch
Fornix publiceert trading update negen maanden 2009
Earnings Release Classification · 99% confidence The document is titled "PERSBERICHT" (Press Release) and contains a headline "FORNIX PUBLICEERT TRADING UPDATE NEGEN MAANDEN 2009" (Fornix Publishes Trading Update Nine Months 2009). It summarizes key financial highlights (net result, revenue) for the first nine months of 2009 and provides an outlook for the full year. This structure—a brief announcement of period results with key figures and commentary—is characteristic of an Earnings Release (ER). It is not a comprehensive report (like 10-K or IR), nor is it a transcript (CT) or a formal presentation (IP). Since it announces the results for a specific period (nine months), it fits the ER category best, which typically covers quarterly or interim period results announcements. 9M 2009
2009-11-05 Dutch
Fornix publiceert trading update negen maanden 2009
Earnings Release Classification · 99% confidence The document is explicitly titled "FORNIX PUBLISHES NINE MONTHS' TRADING UPDATE 2009" and begins with the header "# **P R E S S R E L E A S E**". It provides key financial highlights (turnover, net profit) and operational updates for the first nine months of 2009, along with a forecast for the whole year. This structure—a press release summarizing period results before the full formal report—aligns perfectly with the definition of an Earnings Release (ER). It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), but rather the initial, high-level announcement of period performance. 9M 2009
2009-11-05 Dutch
Aanspraak op vergoeding van ORALGEN® producten in hoger beroep bevestigd
Legal Proceedings Report Classification · 98% confidence The document is titled "PERSBERICHT" (Press Release) and announces a legal development: the confirmation of compensation claims for Oralgen® products by the Court of Appeal in The Hague. This is a specific update regarding a legal matter involving the company and the State of the Netherlands concerning drug reimbursement. This fits best under the category for updates on significant lawsuits or regulatory actions, which is Legal Proceedings Report (LTR). It is not a comprehensive financial report (10-K, IR), an earnings announcement (ER), or a general regulatory filing (RNS), as it details a specific legal outcome.
2009-09-23 Dutch
Entitlement to reimbursment for ORALGEN® products confirmed on appeal
Legal Proceedings Report Classification · 95% confidence The document is clearly labeled as a 'PRESS RELEASE' and announces a specific legal/regulatory outcome regarding drug reimbursement ('ENTITLEMENT TO REIMBURSEMENT FOR ORALGEN® PRODUCTS CONFIRMED ON APPEAL'). It details a court ruling from the Court of The Hague concerning the State of the Netherlands' obligation to reimburse patients for specific allergen products until a future date or decision. This type of announcement, concerning legal proceedings, regulatory decisions impacting operations, or specific contractual/legal outcomes, fits best under the 'Legal Proceedings Report' (LTR) category, as it is a direct update on a significant legal matter. It is not a comprehensive financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS). Given its specific nature regarding a legal dispute outcome, LTR is the most precise fit.
2009-09-23 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.